{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:32:20Z","timestamp":1783110740790,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Joint Programme on Rare Diseases","award":["Improve-PSP"],"award-info":[{"award-number":["Improve-PSP"]}]},{"name":"German Federal Ministry of Education and Research","award":["BMBF: 01KU1403A EpiPD"],"award-info":[{"award-number":["BMBF: 01KU1403A EpiPD"]}]},{"name":"German Federal Ministry of Education and Research","award":["01EK1605A HitTau"],"award-info":[{"award-number":["01EK1605A HitTau"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2145 SyNergy \u2013 ID 390857198"],"award-info":[{"award-number":["EXC 2145 SyNergy \u2013 ID 390857198"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DFG grants","award":["HO2402\/6-2"],"award-info":[{"award-number":["HO2402\/6-2"]}]},{"name":"DFG grants","award":["HO2402\/18-1 MSAomics"],"award-info":[{"award-number":["HO2402\/18-1 MSAomics"]}]},{"name":"Nieders\u00e4chsisches Ministerium f\u00fcr Wissenschaft und Kunst (MWK)\/VolkswagenStiftung"},{"name":"Petermax-M\u00fcller Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Measuring disease progression in clinical trials for testing novel treatments for multifaceted diseases as progressive supranuclear palsy (PSP), remains challenging. In this study we assess a range of statistical approaches to compare outcomes as measured by the items of the progressive supranuclear palsy rating scale (PSPRS). We consider several statistical approaches, including sum scores, a modified PSPRS rating scale that had been recommended by FDA in a pre-IND meeting, multivariate tests, and analysis approaches based on multiple comparisons of the individual items. In addition, we propose two novel approaches which measure disease status based on Item Response Theory models. We assess the performance of these tests under various scenarios in an extensive simulation study and illustrate their use with a re-analysis of the ABBV-8E12 clinical trial. Furthermore, we discuss the impact of the FDA-recommended scoring of item scores on the power of the statistical tests. We find that classical approaches as the PSPRS sum score demonstrate moderate to high power when treatment effects are consistent across the individual items. The tests based on Item Response Theory (IRT) models yield the highest power when the simulated data are generated from an IRT model. The multiple testing based approaches have a higher power in settings where the treatment effect is limited to certain domains or items. The study demonstrates that there is no one-size-fits-all testing procedure for evaluating treatment effects using PSPRS items; the optimal method varies based on the specific effect size patterns. The efficiency of the PSPRS sum score, while generally robust and straightforward to apply, varies depending on the specific patterns of effect sizes encountered and more powerful alternatives are available in specific settings. These findings can have important implications for the design of future clinical trials in PSP and similar multifaceted diseases.<\/jats:p>","DOI":"10.1038\/s41598-024-76668-4","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T18:01:54Z","timestamp":1729965714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficiency of multivariate tests in trials in progressive supranuclear palsy"],"prefix":"10.1038","volume":"14","author":[{"given":"Elham","family":"Yousefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Gewily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Hopfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Ristl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zehetmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Posch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"76668_CR1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, \u201cMultiple endpoints in clinical trials guidance for industry draft guidance,\u201d (2017). https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm536750.pdf."},{"issue":"6","key":"76668_CR2","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","volume":"130","author":"LI Golbe","year":"2007","unstructured":"Golbe, L. I. & Ohman-Strickland, P. A. A clinical rating scale for progressive supranuclear palsy. Brain 130(6), 1552\u20131565 (2007).","journal-title":"Brain"},{"issue":"7","key":"76668_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"AL Boxer","year":"2014","unstructured":"Boxer, A. L. et al. Davunetide in patients with progressive supranuclear palsy: A randomised, double-blind, placebo-controlled phase 2\/3 trial. Lancet Neurol. 13(7), 676\u2013685 (2014).","journal-title":"Lancet Neurol."},{"issue":"4","key":"76668_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mds.25824","volume":"29","author":"E Tolosa","year":"2014","unstructured":"Tolosa, E. et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov. Disord. 29(4), 470\u2013478 (2014).","journal-title":"Mov. Disord."},{"issue":"8","key":"76668_CR5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00415-016-8169-1","volume":"263","author":"G Nuebling","year":"2016","unstructured":"Nuebling, G. et al. Prospera: A randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J. Neurol. 263(8), 1565\u20131574 (2016).","journal-title":"J. Neurol."},{"issue":"8","key":"76668_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","volume":"27","author":"T Dam","year":"2021","unstructured":"Dam, T. et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: A phase 2, randomized, placebo-controlled trial. Nat. Med. 27(8), 1451\u20131457 (2021).","journal-title":"Nat. Med."},{"issue":"3","key":"76668_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","volume":"20","author":"GU H\u00f6glinger","year":"2021","unstructured":"H\u00f6glinger, G. U. et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: A phase 2, randomised, placebo-controlled trial. Lancet Neurol. 20(3), 182\u2013192 (2021).","journal-title":"Lancet Neurol."},{"key":"76668_CR8","doi-asserted-by":"publisher","first-page":"101644","DOI":"10.1016\/j.pneurobio.2019.101644","volume":"180","author":"TW Roesler","year":"2019","unstructured":"Roesler, T. W. et al. Four-repeat tauopathies. Prog. Neurobiol. 180, 101644 (2019).","journal-title":"Prog. Neurobiol."},{"issue":"5","key":"76668_CR9","first-page":"61","volume":"113","author":"J Levin","year":"2016","unstructured":"Levin, J., Kurz, A., Arzberger, T., Giese, A. & H\u00f6glinger, G. U. The differential diagnosis and treatment of atypical parkinsonism. Deutsches \u00c4 rzteblatt Int. 113(5), 61 (2016).","journal-title":"Deutsches \u00c4 rzteblatt Int."},{"issue":"4","key":"76668_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2307\/2531158","volume":"40","author":"PC O\u2019Brien","year":"1984","unstructured":"O\u2019Brien, P. C. Procedures for comparing samples with multiple endpoints. Biometrics 40(4), 1079\u20131087 (1984).","journal-title":"Biometrics"},{"issue":"1","key":"76668_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/03610919608813301","volume":"25","author":"P Reitmeir","year":"1996","unstructured":"Reitmeir, P. & Wassmer, G. One-sided multiple endpoint testing in two-sample comparisons. Commun. Stat.-Simul. Comput. 25(1), 99\u2013117 (1996).","journal-title":"Commun. Stat.-Simul. Comput."},{"issue":"1","key":"76668_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10543406.2018.1489402","volume":"29","author":"R Ristl","year":"2019","unstructured":"Ristl, R., Urach, S., Rosenkranz, G. & Posch, M. Methods for the analysis of multiple endpoints in small populations: A review. J. Biopharm. Stat. 29(1), 1\u201329 (2019).","journal-title":"J. Biopharm. Stat."},{"key":"76668_CR13","unstructured":"Rasch, G. Studies in Mathematical Psychology: I. Probabilistic Models for Some Intelligence and Attainment tests (1960)."},{"key":"76668_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30001","author":"M Gewily","year":"2024","unstructured":"Gewily, M. et al. Quantitative comparisons of progressive supranuclear palsy rating scale versions using item response theory. Mov. Disord.[SPACE]https:\/\/doi.org\/10.1002\/mds.30001 (2024).","journal-title":"Mov. Disord."},{"issue":"24","key":"76668_CR15","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1002\/sim.2682","volume":"25","author":"S Senn","year":"2006","unstructured":"Senn, S. Change from baseline and analysis of covariance revisited. Stat. Med. 25(24), 4334\u20134344 (2006).","journal-title":"Stat. Med."},{"issue":"4","key":"76668_CR16","first-page":"581","volume":"32","author":"L Siemons","year":"2014","unstructured":"Siemons, L. & Krishnan, E. A short tutorial on item response theory in rheumatology. Clin. Exp. Rheumatol. 32(4), 581\u2013586 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"76668_CR17","first-page":"205","volume":"7","author":"S Ueckert","year":"2018","unstructured":"Ueckert, S. Modeling composite assessment data using item response theory. CPT: Pharmacomet. Syst. Pharmacol. 7(4), 205\u2013218 (2018).","journal-title":"CPT: Pharmacomet. Syst. Pharmacol."},{"issue":"1","key":"76668_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/014662169501900105","volume":"19","author":"D Thissen","year":"1995","unstructured":"Thissen, D., Pommerich, M., Billeaud, K. & Williams, V. S. Item response theory for scores on tests including polytomous items with ordered responses. Appl. Psychol. Measurement 19(1), 39\u201349 (1995).","journal-title":"Appl. Psychol. Measurement"},{"key":"76668_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v048.i06","volume":"48","author":"RP Chalmers","year":"2012","unstructured":"Chalmers, R. P. Mirt: A multidimensional item response theory package for the r environment. J. Stat. Softw. 48, 1\u201329 (2012).","journal-title":"J. Stat. Softw."},{"issue":"2","key":"76668_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1467-9876.2011.01005.x","volume":"61","author":"CB Pipper","year":"2012","unstructured":"Pipper, C. B., Ritz, C. & Bisgaard, H. A versatile method for confirmatory evaluation of the effects of a covariate in multiple models. J. R. Stat. Soc. Ser. C: Appl. Stat. 61(2), 315\u2013326 (2012).","journal-title":"J. R. Stat. Soc. Ser. C: Appl. Stat."},{"issue":"1","key":"76668_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/pst.268","volume":"7","author":"NS Dallow","year":"2008","unstructured":"Dallow, N. S., Leonov, S. L. & Roger, J. H. Practical usage of O\u2019Brien\u2019s OLS and GLS statistics in clinical trials. Pharm. Stat. 7(1), 53\u201368 (2008).","journal-title":"Pharm. Stat."},{"key":"76668_CR22","doi-asserted-by":"publisher","DOI":"10.1201\/9781584889854","volume-title":"Multiple Testing Problems in Pharmaceutical Statistics","author":"A Dmitrienko","year":"2009","unstructured":"Dmitrienko, A., Tamhane, A. C. & Bretz, F. Multiple Testing Problems in Pharmaceutical Statistics (CRC Press, 2009)."},{"key":"76668_CR23","first-page":"76","volume":"47","author":"BR Logan","year":"2004","unstructured":"Logan, B. R. & Tamhane, A. C. On O\u2019Brien\u2019s OLS and GLS tests for multiple endpoints. Lect. Notes-Monogr. Ser. 47, 76\u201388 (2004).","journal-title":"Lect. Notes-Monogr. Ser."},{"issue":"3","key":"76668_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/biomet\/73.3.751","volume":"73","author":"RJ Simes","year":"1986","unstructured":"Simes, R. J. An improved bonferroni procedure for multiple tests of significance. Biometrika 73(3), 751\u2013754 (1986).","journal-title":"Biometrika"},{"issue":"2","key":"76668_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/biomet\/75.2.383","volume":"75","author":"G Hommel","year":"1988","unstructured":"Hommel, G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 75(2), 383\u2013386 (1988).","journal-title":"Biometrika"},{"issue":"8","key":"76668_CR26","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1177\/0962280218768326","volume":"28","author":"A Futschik","year":"2019","unstructured":"Futschik, A., Taus, T. & Zehetmayer, S. An omnibus test for the global null hypothesis. Stat. Methods Med. Res. 28(8), 2292\u20132304 (2019).","journal-title":"Stat. Methods Med. Res."},{"issue":"3","key":"76668_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/bimj.201900040","volume":"63","author":"V Vickerstaff","year":"2021","unstructured":"Vickerstaff, V., Ambler, G. & Omar, R. Z. A comparison of methods for analysing multiple outcome measures in randomised controlled trials using a simulation study. Biometr. J. 63(3), 599\u2013615 (2021).","journal-title":"Biometr. J."},{"issue":"2","key":"76668_CR28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.2307\/2576010","volume":"53","author":"KW Smith","year":"1974","unstructured":"Smith, K. W. Forming composite scales and estimating their validity through factor analysis. Soc. Forces 53(2), 168\u2013180 (1974).","journal-title":"Soc. Forces"},{"key":"76668_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40263-016-0347-2","volume":"30","author":"M Stamelou","year":"2016","unstructured":"Stamelou, M. & H\u00f6glinger, G. A review of treatment options for progressive supranuclear palsy. CNS Drugs 30, 629\u2013636 (2016).","journal-title":"CNS Drugs"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76668-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76668-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76668-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T18:04:18Z","timestamp":1729965858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76668-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["76668"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-76668-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.H. has ongoing research collaborations with Roche, UCB, Abbvie; serves as a consultant for Abbvie, Alzprotect, Amylyx, Aprineua, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, UCB; received honoraria for scientific presentations from Abbvie, Bayer, Bial, Biogen, Bristol Myers Squibb, Kyowa Kirin, Pfizer, Roche, Teva, UCB, Zambon; holds a patent on Treatment of Synucleinopathies (US 10,918,628 B2, EP 17 787 904.6-1109 \/ 3 525 788); received publication royalties from Academic Press, Kohlhammer, and Thieme.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25581"}}